AUNP-12 acetate
Code | Size | Price |
---|
TAR-TP1076L-1mg | 1mg | £164.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1076L-5mg | 5mg | £332.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1076L-10mg | 10mg | £463.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1076L-25mg | 25mg | £711.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1076L-50mg | 50mg | £946.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1076L-100mg | 100mg | £1,259.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity.
CAS:
0
Formula:
C144H230N40O50
Molecular Weight:
3321.61
Pathway:
Apoptosis; Immunology/Inflammation; Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
O=C([C@@](C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])([H])N([H])C([C@](C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(O[H])=O)([H])N([H])N([H])[H])=O)=O)=O)=O)=O)N1[C@@](C(N([H])[C@](C(C([C@@](C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])O[H])([H])N([H])C([C@@](C(C([H])([H])[H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C([H])([H])N([H])/C(N([H])[H])=N/[H])([H])N([H])C([C@@](C([H])([H])C2=C([H])C([H])=C([H])C([H])=C2[H])([H])N([H])C(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])N([H])[C@@](C(N([H])[C@](C([H])([H])O[H])([H])C(N([H])[C@@](C(N([H])[C@](C([H])([H])O[H])([H])C(N([H])[C@@](C(N([H])[C@@](C(N([H])[C@@](C([H])=O)([H])C([H])([H])O[H])=O)([H])C([H])([H])C(N([H])[H])=O)=O)([H])[C@@](C([H])([H])[H])([H])O[H])=O)=O)([H])C([H])([H])C([H])([H])C(O[H])=O)=O)=O)([H])C([H])([H])C3=C([H])C([H])=C([H])C([H])=C3[H])([H])N([H])C([C@@](C([H])([H])C4=C([H])C([H])=C([H])C([H])=C4[H])([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(O[H])=O)([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])O[H])([H])N([H])C([C@@](C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)([H])C([H])([H])[H])=O)([H])C([H])([H])C([H])([H])C1([H])[H].CC(O)=O
Target:
PD-1/PD-L1
References
Pottayil G Sasikumar, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.